Ani Pharmaceuticals (ANIP) Cash & Equivalents (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Cash & Equivalents data on file, last reported at $311.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 107.72% year-over-year to $311.2 million; the trailing twelve-month figure through Mar 2026 stood at $311.2 million (up 107.72% YoY), and the FY2025 full-year result was $285.6 million, up 97.14% from the prior year.
• Cash & Equivalents climbed to $311.2 million in Q1 2026, from $285.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $311.2 million in Q1 2026 to a low of $48.2 million in Q4 2022.
• A 5-year average of $169.1 million and a median of $161.7 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 51.92% in 2022 and jumped 358.49% in 2023, its largest moves.
• Tracing ANIP's Cash & Equivalents over 5 years: stood at $48.2 million in 2022, then surged by 358.49% to $221.1 million in 2023, then tumbled by 34.49% to $144.9 million in 2024, then surged by 97.14% to $285.6 million in 2025, then gained by 8.96% to $311.2 million in 2026.
• Business Quant data shows ANIP's Cash & Equivalents at $311.2 million in Q1 2026, $285.6 million in Q4 2025, and $262.6 million in Q3 2025.